Meleagrin, a new fabi inhibitor from Penicillium chryosogenum with at least one additional mode of action

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zheng, Chang Ji ^a   Sohn, Mi Jin ^a   Lee, Sangku ^a   Kim, Won Gon ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINONIN; AMPICILLIN; ANTIINFECTIVE AGENT; BACTERIAL ENZYME; ERYTHROMYCIN; FATTY ACID; MELEAGRIN; NORFLOXACIN; OXACILLIN; PROTEIN FABI; PROTEIN FABI INHIBITOR; PROTEIN FABK; TRICLOSAN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ISOLATION; DRUG MECHANISM; DRUG SCREENING; ESCHERICHIA COLI; FATTY ACID SYNTHESIS; FLUORESCENCE; IC 50; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PENICILLIUM CHRYSOGENUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOSYNTHETIC PATHWAYS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; ESCHERICHIA COLI; FATTY ACIDS; GENE EXPRESSION; MICROBIAL SENSITIVITY TESTS; MUTATION; OVOMUCIN; PENICILLIUM CHRYSOGENUM; STAPHYLOCOCCUS AUREUS;

EID: 84896703765     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078922     Document Type: Article

References (32)

1. Klein E, Smith DL, Laxminarayan R (2007) Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13: 1840-1846. (Pubitemid 350248484)
2. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10: S122-129. (Pubitemid 40018235)
3. Miesel L, Greene J, Black TA (2003) Genetic strategies for antibacterial drug discovery. Nat Rev Genet 4: 442-456. (Pubitemid 36648144)
4. Heath RJ, Rock CO (2004) Fatty acid biosynthesis as a target for novel antibacterials. Curr Opin Investig Drugs 5: 146-153.
5. Wang J, Soisson SM, Young K, Shoop W, Kodali S, et al. (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441: 358-361. (Pubitemid 44050201)
6. Massengo-Tiasse RP, Cronan JE (2008) Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase. Journal of Biological Chemistry 283: 1308-1316.
7. Zhu L, Lin J, Ma J, Cronan JE, Wang H (2010) Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase. Antimicrobial Agents and Chemotherapy 54: 689-698.
8. Zhang YM, White SW, Rock CO (2006) Inhibiting bacterial fatty acid synthesis. J Biol Chem 281: 17541-17544. (Pubitemid 44035552)
9. Lu H, Tonge PJ (2008) Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc Chem Res 41: 11-20.
10. Silver LL (2007) Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6: 41-55.
11. McMurry LM, Oethinger M, Levy SB (1998) Triclosan targets lipid synthesis. Nature 394: 531-532.
12. Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC (1998) Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279: 98-102. (Pubitemid 28079164)
13. Cardoso RF, Cooksey RC, Morlock GP, Barco P, Cecon L, et al. (2004) Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. Antimicrob Agents Chemother 48: 3373-3381. (Pubitemid 39129333)
14. Hazbon MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, et al. (2006) Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 50: 2640-2649. (Pubitemid 44198682)
15. Chen Y, Pi B, Zhou H, Yu Y, Li L (2009) Triclosan resistance in clinical isolates of Acinetobacter baumannii. Journal of Medical Microbiology 58: 1086-1091.
16. Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, et al. (2011) The MUT056399 Inhibitor of FabI Is a New Antistaphylococcal Compound. Antimicrob Agents Chemother 55: 4692-4697.
17. Silver LL (2011) Challenges of antibacterial discovery. Clin Microbiol Rev 24: 71-109.
18. Livermore DM (2011) Discovery research: the scientific challenge of finding new antibiotics. Journal of Antimicrobial Chemotherapy 66: 1941-1944.
19. Singh MP, Greenstein M (2000) Antibacterial leads from microbial natural products discovery. Curr Opin Drug Discov Devel 3: 167-176. (Pubitemid 30214541)
20. Zheng CJ, Sohn MJ, Lee S, Hong YS, Kwak JH, et al. (2007) Cephalochromin, a FabI-directed antibacterial of microbial origin. Biochemical and Biophysical Research Communications 362: 1107-1112. (Pubitemid 47390690)
21. Zheng CJ, Sohn MJ, Kim WG (2009) Vinaxanthone, a new FabI inhibitor from Penicillium sp. Journal of Antimicrobial Chemotherapy 63: 949-953.
22. Mattheus W, Masschelein J, Gao LJ, Herdewijn P, Landuyt B, et al. (2010) The kalimantacin/batumin biosynthesis operon encodes a self-resistance isoform of the FabI bacterial target. Chemistry and Biology 17: 1067-1071.
23. Kawai K, Nozawa K, Nakajima S, Iitaka Y (1984) Studies on fungal products. VII. The structures of meleagrin and 9-O-p-bromobenzoylmeleagrin. Chemical and Pharmaceutical Bulletin 32: 94-98. (Pubitemid 14195353)
24. Zheng CJ, Yoo JS, Lee TG, Cho HY, Kim YH, et al. (2005) Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Letters 579: 5157-5162. (Pubitemid 41318085)
25. Guzman LM, Belin D, Carson MJ, Beckwith J (1995) Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. Journal of Bacteriology 177: 4121-4130.
26. Sivaraman S, Zwahlen J, Bell AF, Hedstrom L, Tonge PJ (2003) Structureactivity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs. Biochemistry 42: 4406-4413. (Pubitemid 36457608)
27. Slater-Radosti C, Van Aller G, Greenwood R, Nicholas R, Keller PM, et al. (2001) Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. J Antimicrob Chemother 48: 1-6. (Pubitemid 32684718)
28. Nozawa K, Nakajima S (1979) Isolation of radicicol from Penicillium Luteo-Aurantium, and Meleagrin, a new metabolite, from Penicillium Meleagrinum. Journal of Natural Products 42: 374-377.
29. Bringmann G, Lang G, Gulder TAM, Tsuruta H, Mu?hlbacher J, et al. (2005) The first sorbicillinoid alkaloids, the antileukemic sorbicillactones A and B, from a sponge-derived Penicillium chrysogenum strain. Tetrahedron 61: 7252-7265. (Pubitemid 40840632)
30. Moir DT (2005) Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase. Curr Drug Targets Infect Disord 5: 297-305.
31. Zheng CJ, Sohn MJ, Lee S, Hong YS, Kwak JH, et al. (2007) Cephalochromin, a FabI-directed antibacterial of microbial origin. Biochem Biophys Res Commun 362: 1107-1112. (Pubitemid 47390690)
32. Zhang YM, Rock CO (2004) Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase. J Biol Chem 279: 30994-31001.